tirzepatide scholarly articles on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Tirzepatide after intensive lifestyle intervention

Ozempic is approved to lower blood sugar in adults with type 2 diabetes and to reduce the risk of heart attack or stroke in patients with diabetes and heart disease

Adjusting Your Dose Test results often lead to dose changes

Sublingual semaglutide is a medication used for weight loss

A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone